Neonatal effects of maternal nadolol therapy

Described is the case of an infant, exposed during gestation to the beta-blocker nadolol, who experienced cardiorespiratory depression, mild hypoglycemia, and growth retardation. The longer duration of action of nadolol and the fact that it is only 30% protein bound make it less desirable than propranolol for use as a beta-blocker during pregnancy.